High-dose methotrexate-based chemotherapy for induction remission of newly diagnosed primary CNS lymphoma: A systematic review and meta-analysis.

ABSTRACT:

Background

This study aimed to comprehensively assess the optimal regimen for high-dose methotrexate (HD-MTX) in treating primary central nervous system lymphoma (PCNSL).

Methods

We have searched 8 databases, including PubMed, EMBASE, Cochrane Library, WOS, Epistemonikos, CNKI, WAN-FANG Database, and CBM, and were selected for the clinical trials about PCNSL. A total of 37 studies were included in our analysis, consisting of 6 randomized controlled trials and 31 single-arm clinical studies.

Results

After analyzing the data from 37 clinical studies, we found that the pooled overall response rate (ORR) for low-dose (<3 g/m2), medium-dose (3-5 g/m2), and high-dose (>5 g/m2) methotrexate (MTX) were 0.78, 0.80, and 0.80, respectively. The pooled 2-year overall survival (OS

SUBMITTER: Shi H 

PROVIDER: S-EPMC11789877 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature